PolicyWinds
Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on. How labels work
Federal · 119th Congress

HR679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Direction

Abortion medication abortionAI label

Restricts abortion access model confidence 90%

Nullifies the FDA's 2023 REMS modifications for mifepristone (which had eased dispensing and mailing rules) and bars similar future changes, so less medication-abortion access.

The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone are hereby nullified.

✓ Quote verified word for word in the bill text

Abortion provider clinic regulationAI label

Restricts abortion access model confidence 80%

Nullifies the FDA's 2023 REMS modifications for mifepristone (which had eased dispensing and mailing rules) and bars similar future changes, so more provider and clinic restrictions on medication abortion.

The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone are hereby nullified.

✓ Quote verified word for word in the bill text

  1. Introduced (completed)
  2. Committee
  3. Passed one chamber
  4. Passed both
  5. President
  6. Law

Stage: Committee · step 2 of 6

Last action
2025-01-23: Referred to the House Committee on Energy and Commerce.
Filed
2025-01-23
Committee
Energy and Commerce Committee
Sponsor
Diana Harshbarger R + 18 cosponsors (18 R)

Why the model tagged it this way: The bill directly targets the FDA's January 2023 REMS changes for the abortion pill mifepristone by nullifying them and prohibiting substantially similar provisions, which had expanded access by allowing pharmacy dispensing and mail-order without in-person requirements; this reverses those changes and restricts medication abortion access and related provider regulations.

Related bills

Sponsors

Text versions

History (3 actions)
DateChamberAction
2025-01-23LibraIntroduced in House
2025-01-23LibraIntroduced in House
2025-01-23HouseReferred to the House Committee on Energy and Commerce.